CLINICAL TRIALS PROFILE FOR BUPRENORPHINE HYDROCHLORIDE

505(b)(2) Clinical Trials for BUPRENORPHINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00637000 ↗	Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone	Completed	Indivior Inc.	Phase 2	2008-03-01	The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.
New Dosage	NCT03608696 ↗	Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure	Completed	Chiesi Farmaceutici S.p.A.	Phase 1/Phase 2	2018-08-29	Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
New Dosage	NCT03608696 ↗	Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure	Completed	Thomas Jefferson University	Phase 1/Phase 2	2018-08-29	Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.

All Clinical Trials for BUPRENORPHINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000200 ↗	Cocaine Effects in Humans: Physiology and Behavior - 1	Completed	Columbia University	Phase 2	1997-01-01	The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000200 ↗	Cocaine Effects in Humans: Physiology and Behavior - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1997-01-01	The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000202 ↗	Buprenorphine Maintenance for Opioid Addicts - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1988-08-01	The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
NCT00000202 ↗	Buprenorphine Maintenance for Opioid Addicts - 1	Completed	Yale University	Phase 2	1988-08-01	The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
NCT00000203 ↗	Buprenorphine Maintenance for Opioid Addicts - 2	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1988-08-01	The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.

Clinical Trial Conditions for BUPRENORPHINE HYDROCHLORIDE

Condition Name

Condition Name for BUPRENORPHINE HYDROCHLORIDE
Intervention	Trials
Opioid-Related Disorders	95
Opioid Use Disorder	74
Opioid-Use Disorder	45
Opioid Dependence	40

Condition MeSH

Condition MeSH for BUPRENORPHINE HYDROCHLORIDE
Intervention	Trials
Opioid-Related Disorders	307
Substance-Related Disorders	83
Disease	51
Heroin Dependence	33

Clinical Trial Locations for BUPRENORPHINE HYDROCHLORIDE

Trials by Country

Trials by Country for BUPRENORPHINE HYDROCHLORIDE
Location	Trials
Japan	29
United Kingdom	28
Canada	13
Germany	12
Australia	8

Trials by US State

Trials by US State for BUPRENORPHINE HYDROCHLORIDE
Location	Trials
New York	99
California	81
Maryland	74
Pennsylvania	72
Florida	66

Clinical Trial Progress for BUPRENORPHINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for BUPRENORPHINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	14
PHASE3	5
PHASE2	13

Clinical Trial Status

Clinical Trial Status for BUPRENORPHINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	305
Recruiting	87
Not yet recruiting	43

Clinical Trial Sponsors for BUPRENORPHINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for BUPRENORPHINE HYDROCHLORIDE
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	182
Yale University	40
Indivior Inc.	31

Sponsor Type

Sponsor Type for BUPRENORPHINE HYDROCHLORIDE
Sponsor	Trials
Other	553
Industry	211
NIH	196

BUPRENORPHINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 16, 2026

What Is the Current Status of Clinical Trials for Buprenorphine Hydrochloride?

Buprenorphine hydrochloride is a semi-synthetic opioid used primarily for pain management and opioid use disorder (OUD). Multiple clinical trials are ongoing or completed, focusing on efficacy, safety, and new formulations.

• Ongoing Trials: As of Q1 2023, over 20 clinical trials examine buprenorphine hydrochloride's various applications, including novel delivery systems, overdose prevention, and pediatric use (ClinicalTrials.gov).

• Key Completed Trials:

  • A Phase 3 trial (NCT04531926) published in 2022 evaluated buprenorphine transdermal patches, demonstrating non-inferiority to sublingual formulations in OUD treatment.
  • Another Phase 3 trial assessed buprenorphine implant devices, with results indicating high adherence and sustained opioid blockade.

• Regulatory Approvals: The FDA approved Sublocade (buprenorphine extended-release injection) in 2017 and Bunavail (buprenorphine/naloxone buccal film) in 2018. Ongoing studies aim for approval of new formulations or expanded indications, particularly in pain management.

How Is the Market for Buprenorphine Hydrochloride Evolving?

Market Segments

• Opioid Use Disorder (OUD): The dominant segment, accounting for approximately 70% of sales globally in 2022.
• Pain Management: Growing segment driven by need for alternative to systemic opioids, especially in chronic pain.

Regional Analysis

Region	Market Share (2022)	Growth Rate (CAGR 2022-2028)	Regulatory Environment
North America	55%	6.2%	Established approvals and reimbursement infrastructure
Europe	25%	5.4%	Pending approvals for novel formulations
Asia-Pacific	12%	8.0%	Emerging market; increasing regulatory approvals
Rest of World	8%	7.4%	Variable regulatory landscape

Market Drivers

• Rising incidence of opioid dependence
• Expanded approval for long-acting formulations
• Increased awareness about medication-assisted treatment (MAT)

Competitive Landscape

• Major players include Indivior, Camurus, Purdue Pharma, and Braeburn Pharmaceuticals.
• Indivior's Sublocade holds a 40% market share in long-acting formulations as of 2022.
• Entry of generic alternatives expected by 2025 following patent expiries.

What Are the Future Market Projections?

• The global buprenorphine market is projected to reach USD 4.8 billion by 2028, growing at approximately 6.0% CAGR from USD 3.2 billion in 2022 (Research and Markets).

• Long-acting formulations will represent over 50% of the market by 2028, driven by patient adherence issues and regulatory push for sustained-release options.

• In pain management, increased use of buprenorphine patches and implants is anticipated to offset declining use of sublingual tablets.

• Emerging markets in Asia-Pacific will account for a larger share—projected to reach 15% of total sales by 2028, up from 12% in 2022.

What Regulatory Trends Are Influencing Market Growth?

• Expansion of approved indications, including postoperative pain and opioid dependence in pediatric populations.
• Push for more tamper-resistant formulations to reduce diversion.
• Policy shifts favoring medication-assisted treatment over opioid prescribing.

What Are the Challenges?

• Stringent regulatory scrutiny post-2020 over diversion and misuse.
• Patent expiries threaten revenue streams, prompting innovation in formulation.
• Pricing pressures from healthcare systems seeking cost-effective options.

Key Takeaways

• Buprenorphine hydrochloride remains central to managing opioid dependence, with ongoing trials exploring new formulations.
• The market is set to grow at around 6% annually through 2028, reaching nearly USD 5 billion globally.
• Long-acting formulations predominate, driven by patient adherence needs and regulatory incentives.
• Asia-Pacific markets will increasingly influence sales, with growing acceptance and regulatory approvals.
• Patent expiries and competitive pressures necessitate innovation in drug delivery and formulations.

FAQs

1. What new formulations of buprenorphine hydrochloride are in clinical trials?
Sustained-release implants and novel transdermal patches are the focus, aiming to improve adherence and reduce diversion.

2. How does regulation impact market growth?
Stringent controls on diversion and abuse influence approval processes and formulation development, impacting availability and sales.

3. What are the most significant competitors?
Indivior's Sublocade and Camurus's Brixadi are leading long-acting products; generic versions are expected after patent expiries.

4. Which markets show the fastest growth?
Asia-Pacific exhibits the highest CAGR (~8%) due to expanding healthcare infrastructure and increasing acceptance of MAT.

5. How might patent expiries affect the market?
Generic competition starting around 2025 could reduce prices and erode branded product revenue, incentivizing innovation.

---

Sources
[1] ClinicalTrials.gov, "Buprenorphine Studies," 2023.
[2] Research and Markets, "Global Buprenorphine Market Report," 2023.
[3] U.S. FDA approvals, 2017-2018.